Amgen lines up new AI biotech partner in PostEra to develop small molecule medicines

Am­gen is en­list­ing AI start­up PostEra for a drug dis­cov­ery deal for five small mol­e­cule pro­grams, PostEra an­nounced Thurs­day morn­ing.

Few de­tails about the col­lab­o­ra­tion were made avail­able. PostEra CEO Aaron Mor­ris de­clined to com­ment on the deal val­ue in an in­ter­view with End­points News. How­ev­er, he de­scribed it as the “most mean­ing­ful part­ner­ship we’ve done to date,” and added that it brings the to­tal deal val­ue PostEra has closed to over $1 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.